

Oncology Drugs Import of Turkey: Trends and Updates of 2024

Oncology drugs, the medicines that are used to treat cancer, are being traded in large amounts in the global market due to their widespread use in healthcare facilities. The uneven global production capacity and the rising global cancer burden, along with the high R&D and manufacturing specialization, have maintained continuity in the global trade of oncology drugs. Turkey, a transcontinental country on the Anatolian Peninsula bordered by Armenia and Syria in the east and south direction, has recorded itself as a leading importer of oncology drugs due to the government policies prioritizing access to innovative treatments and the requirements to match European oncology treatment guidelines.



Due to the demand for precision oncology medicines and the strategies initiated by the government authorities to participate in global medicine, the country has imported oncology drugs worth 2 billion US dollars in 2024. The expansion of personalized medicine and precision oncology, along with the expansion of the national cancer treatment coverage, has benefited the overall import revenue. Subscribe to Import Globals, the leading [Turkey Export Data](#) provider, to stay updated with the latest information regarding the oncology drugs import of the nation via the Turkey trade data.

GOVERNMENT INITIATIVES SUPPORTING THE IMPORT OF ONCOLOGY DRUGS IN TURKEY IN 2024

The Named Patient Program introduced by the government has enabled the reliable access of the domestic authorities to critical cancer treatments, providing different alternatives to the population regarding life-saving medicines. The Compassionate Health Program has improved the treatment options in critical cases.

The regulatory update to NPT guidelines has lowered the barriers for patients and doctors for effective use in healthcare facilities. The 12th National Development Plan has prioritized pharmaceuticals in economic planning by introducing innovative medicines to help the authorities maintain a reliable supply index.

THE LEADING VARIANTS OF ONCOLOGY DRUGS IMPORTED IN TURKEY IN 2024

The growing private sector investments and the competitive pricing strategies followed by the domestic authorities have introduced diversity in global investment. According to the [Turkey Import Data](#), the top 10 variants of oncology drugs imported in the nation in 2024 are,

- Trastuzumab – The total valuation of Trastuzumab imported in Turkey in 2024 – 918 million US dollars
- Bevacizumab – The total valuation of Bevacizumab imported in Turkey in 2024 – 826 million US dollars
- Rituximab – The total valuation of Rituximab imported in Turkey in 2024 – 787 million US dollars
- Cetuximab– The total valuation of Cetuximab imported in Turkey in 2024 – 649 million US dollars
- Pembrolizumab– The total valuation of Pembrolizumab imported in Turkey in 2024 – 587 million US dollars
- Nivolumab – The total valuation of Nivolumab imported in Turkey in 2024 – 476 million US dollars
- Niraparib – The total valuation of Niraparib imported in Turkey in 2024 – 389 million US dollars
- Sotorasib– The total valuation of Sotorasib imported in Turkey in 2024 – 276 million US dollars
- Atezolizumab – The total valuation of Atezolizumab imported in Turkey in 2024 – 225 million US dollars
- Trastuzumab emtansine – The total valuation of Trastuzumab emtansine imported in Turkey in 2024 – 127 million US dollars

TOP 10 IMPORT TRADE PARTNERS OF TURKEY IN 2024

The growing demand of the country for targeted therapies and the faster approval of imported technology have led to trading relationships. According to the [Turkey Customs Data](#), the top 10 import partners of the nation for oncology drug imports in 2024 are

- China – The total valuation of oncology drugs imported in Turkey from China in 2024 – 954 million US dollars

Top 5 variants of oncology drugs imported

1. Daunorubicin
2. Idarubicin
3. Mitoxantrone
4. Cyclophosphamide
5. Ifosfamide

- Russia– The total valuation of oncology drugs imported in Turkey from Russia in 2024 – 865 million US dollars

Top 5 variants of oncology drugs imported

1. Methotrexate
2. 5-Fluorouracil
3. Capecitabine
4. Cytarabine
5. Gemcitabine

- Germany– The total valuation of oncology drugs imported in Turkey from Germany in 2024 – 764 million US dollars

Top 5 variants of oncology drugs imported

1. Venetoclax
2. Ibrutinib
3. Acalabrutinib
4. Zanubrutinib
5. Olaparib

- Italy – The total valuation of oncology drugs imported in Turkey from Italy in 2024 – 614 million US dollars

Top 5 variants of oncology drugs imported

1. Abemaciclib
2. Everolimus
3. Temsirolimus
4. Copanlisib
5. Idelalisib

- United States– The total valuation of oncology drugs imported in Turkey from the United States in 2024 – 580 million US dollars

Top 5 variants of oncology drugs imported

1. Vemurafenib
2. Trametinib
3. Cobimetinib
4. Binimetinib
5. Selumetinib

- France – The total valuation of oncology drugs imported in Turkey from France in 2024 – 476 million US dollars

Top 5 variants of oncology drugs imported

1. Alectinib
2. Brigatinib
3. Lorlatinib
4. Sotorasib

5. Dabrafenib

- Switzerland – The total valuation of oncology drugs imported in Turkey from Switzerland in 2024 – 354 million US dollars

Top 5 variants of oncology drugs imported

1. Osimertinib
2. Afatinib
3. Dacomitinib
4. Crizotinib
5. Ceritinib

- Spain– The total valuation of oncology drugs imported in Turkey from Spain in 2024 – 278 million US dollars

Top 5 variants of oncology drugs imported

1. Brentuximab vedotin
2. Polatuzumab vedotin
3. Lapatinib
4. Erlotinib
5. Gefitinib

- South Korea – The total valuation of oncology drugs imported in Turkey from South Korea in 2024 – 225 million US dollars

Top 5 variants of oncology drugs imported

1. Inotuzumab ozogamicin
2. Gemtuzumab ozogamicin
3. Alemtuzumab
4. Obinutuzumab
5. Ofatumumab

- United Arab Emirates– The total valuation of oncology drugs imported in Turkey from the United Arab Emirates in 2024 – 224 million US dollars

Top 5 variants of oncology drugs imported

1. Ipilimumab
2. Avelumab
3. Daratumumab
4. Elotuzumab
5. Blinatumomab